SINT (sintx.com) Market Value to Book Value Ratio

sintx.com (SINT) - corporate logo

Sintx Technologies (SINT) is advancing the bioceramics environment by integrating ultra-strong silicon nitride into aviation components and prosthetics. Growing interest in wear-resistant materials is expanding the pool of B2B partners among global medtech behemoths. The market valuation dynamics, recorded at 2.12, accompany the company's expansion. The business is currently scaling the production of armor components and implants, aiming to secure a dominant position in the specialized equipment niche.

Market Capitalization to Net Assets: sintx.com (SINT) for 07/04/2022 - 10/27/2026
Finished products of Sintx Technologies

Production robotization of bioceramics at Sintx Technologies (SINT) minimizes costs, creating high value for technological assets. This algorithm compares the company's market value with its net assets, identifying an innovation premium. The 2.12 coefficient demonstrates the degree of business overvaluation relative to the book value of capital. This metric allows for the determination of a fair entry level into the asset. By analyzing the current market capitalization to book value ratio, an investor assesses the risk of overpaying for technological superiority.

Direct competitors

BSX - Market Cap to Net Assets Ratio|EW (edwards.com) - Market Cap to Book Value Multiple|RMD: Market Value to Book Value Ratio|Market Capitalization to Book Value PODD|ZBH - Market Value to Book Value Ratio|Market Capitalization to Net Assets CooperSurgical (COO)|ALGN: Market Capitalization to Book Value Ratio|Market-to-Book Ratio globusmedical.com GMED|TMDX: Market Capitalization to Book Value Ratio|ATEC - Market Cap to Net Assets Ratio|Artivion Inc - Market Capitalization to Book Value Ratio|Enovis Inc. (ENOV) - Market Capitalization to Book Value|IART (Integra LifeSciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ESTA|Market Value to Book Value Ratio Beta Bionics (BBNX)|Market Value to Book Value Ratio IRADIMED Corp (IRMD)|Market Capitalization to Book Value Ratio EMBC|TNDM - Market Capitalization to Book Value|Market Cap to Net Assets Ratio AxoGen, Inc.|SIBN - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio OFIX|Bioventus Inc (BVS) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio OrthoPediatrics Corp (KIDS)|Capitalization to Book Value Ratio Treace Corp (TMCI)|Strata Critical Medical Inc (SRTA) - Market Cap to Net Assets Ratio|Market Value to Book Value CARL (carlsmed.com)|RxSight - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio ClearPoint Neuro Inc. CLPT|STXS (Stereotaxis Corp) - Market Capitalization to Book Value Ratio|STIM - Market-to-Book Ratio|Market Capitalization to Book Value Ratio Sight Sciences, Inc.|orchestrabiomed.com (OBIO) - Capitalization to Book Value Ratio|ANIK: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value InspireMD Inc|Market Capitalization to Book Value Ratio ZJYL (Jin Medical International)|Market Cap to Net Assets Ratio vivani.com (VANI)|Market Capitalization to Book Value Ratio XTNT (Xtant Medical)|n1mtc.com - Market Capitalization to Book Value Ratio|MODD - Market Value to Book Value Ratio|Myomo Inc. (MYO) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Envoy Medical, Inc COCH|Vivos Therapeutics Inc (VVOS) - Market Value to Book Value|Market Capitalization to Book Value Ratio NVNO (enVVeno Medical)|Market-to-Book Ratio TNON|LFWD: Market Value to Book Value Ratio|Market Value to Equity Ratio autonomix.com AMIX|Market Cap to Net Assets Ratio IVF (INVO Bioscience, Inc.)|Market Capitalization to Book Value Ratio Bone Biologics Inc BBLG|Market Capitalization to Book Value Ratio AXNX (Axonics, Inc.)|BIOL: Market Capitalization to Book Value|Market Value to Book Value Ratio dynatronics.com (DYNT)|FNA (Paragon 28) - Market Capitalization to Net Assets|Market Value to Book Value Ratio INVO